[177Lu]Lu-XT771

[177Lu]Lu-XT771 is an investigational radiopharmaceutical being developed by Beijing Tiantan Hospital for the treatment of recurrent glioblastoma. It consists of the targeting ligand XT771 labeled with the beta-emitting radioisotope Lutetium-177. The drug specifically targets Carbonic Anhydrase IX (CA IX) and XII (CA XII), enzymes that are frequently overexpressed in the hypoxic microenvironment of glioblastomas. By binding to these targets, [177Lu]Lu-XT771 delivers localized beta radiation directly to tumor cells. In clinical trials, it is administered locoregionally via an implanted Ommaya reservoir directly into the tumor resection cavity to maximize local efficacy and minimize systemic toxicity. This approach is often paired with a diagnostic counterpart, [68Ga]Ga-XT771, which is used for pre-treatment leakage testing.

Other names

177Lu-XT771